BusinessOncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial ResultsBy Nasdaq OMXMar 8, 2017, 9:06 PM UTC
BusinessOncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial ResultsBy Nasdaq OMXMar 8, 2017, 9:06 PM UTC
BusinessOncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic CancerBy Nasdaq OMXSep 1, 2016, 12:01 PM UTC
BusinessOncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers SymposiumBy Nasdaq OMXJan 22, 2016, 1:30 PM UTC
